Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) rises 157.8% from a year ago
Property, plant & equipment (net) stood at $1.77M at the end of Q1 FY2026, up 157.8% from a year earlier and down 12.7% from the prior quarter. Over 3 fiscal years it compounded at +47.3% a year.
Context
- Property, plant & equipment (net) amounted to 0.3% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Property, plant & equipment (net) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +157.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 2.03M USD
- Year-over-year change
- +140.4%
- 3-year CAGR
- +47.3%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.03M | +140.4% |
| FY2024 | 2024-12-31 | 845K | +3.7% |
| FY2023 | 2023-12-31 | 815K | +28.1% |
| FY2022 | 2022-12-31 | 636K | — |
Property, Plant & Equipment (Net) vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 property, plant & equipment (net) of $1.77M is the 5th highest of the 6 companies compared; the peer median is $2.78M.
- Its year-over-year change of +157.8% is the highest of 5, against a peer median of +30.6%.
- Property, plant & equipment (net) amounts to 0.3% of total assets for BCAX, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $33.97M | -17.1% | -14.5% | 15.6% | |
| Mar 2026 | $8.92M | +32.3% | +26.6% | 4.3% | |
| Mar 2026 | $2.78M | +28.8% | -16.8% | 0.7% | |
| Mar 2026 | $2.3M | — | +45.5% | 1.2% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $1.77M | +157.8% | +47.3% | 0.3% |
| Mar 2026 | $342.28K | +45.9% | +20.8% | 0.6% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $2.78M | +30.6% | +20.8% | 1.2% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.